TechnologyBoard of DirectorsScientific Advisory BoardContact Us
Seeking to Redefine What is Possible in the Treatment of CNS Disorders

Promentis Pharmaceuticals, Inc. is developing novel compounds for the treatment of various central nervous system (CNS) disorders. Promentis' drug development efforts are focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress. Given the very high level of unmet medical need, Promentis is excited to quickly advance through clinical trials with a keen focus on making a meaningful impact in the lives of
patients and their families.